<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Strong evidence points to the role of cancer immunoediting and tumor immune infiltrates in regulating cancer progression. By understanding the immune tumor microenvironment, we can now target key pathways that suppress endogenous antitumor responses, thereby re-instating such immune responses and identifying novel targets for immune therapies. Therapies targeting oncogenic pathways and checkpoint blockades turn on a new paradigm shift in immune-therapy for cancer with remarkable clinical efficacy seen in various malignancies. However, a lot of cancer patients will fail to respond and therefore, it becomes crucial to identify biomarkers to predict who of the patients will most likely benefit from these therapies.</p></abstract>

Strong evidence points to the role of cancer immunoediting and tumor immune infiltrates in regulating cancer progression. By understanding the immune tumor microenvironment, we can now target key pathways that suppress endogenous antitumor responses, thereby re-instating such immune responses and identifying novel targets for immune therapies. Therapies targeting oncogenic pathways and checkpoint blockades turn on a new paradigm shift in immune-therapy for cancer with remarkable clinical efficacy seen in various malignancies. However, a lot of cancer patients will fail to respond and therefore, it becomes crucial to identify biomarkers to predict who of the patients will most likely benefit from these therapies.

Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer

Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens,

Forum of Clinical Oncology

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Strong evidence points to the role of cancer immunoediting and tumor immune infiltrates in regulating cancer progression. By understanding the immune tumor...

STUDY NAME	TARGET ANTIGEN	VACCINE NAME/TYPE	CANCER
IMPACT	PAP	Mo/DCsPAP-GM-CSF	mCRPC
PROSPECT	PSA	PSA-TRICOM	mCRPC
Stimuvax	MUC1	BLPD25	NSCLC
PANVAC	MUC1/CEA	DCsPSA-TRICOM	Colorectal
GVAX	multiple	T47D&SKBR3 lines	Breast
DERMA	MAGE-A3	Rec Protein	Melanoma
MAGRIT	MAGE-A3	Rec Protein	NSCLC
IMPRINT	11 tumour peptides	soluble	Renal
TG4010	MUC1	MVA MUC-1-IL-2	Prostate NSCLC
CDX110	EGFRvIII	Soluble 13-mer	Glioblastoma

Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer

Article Category: Research Article

Published Online: Sep 17, 2016

Page range: 4 - 16

Received: Feb 24, 2016

Accepted: Aug 04, 2016

DOI: https://doi.org/10.1515/fco-2016-0005

Keywords
Cancer immunotherapy, Tumor infiltrating lymphocytes, Immunoscore, Cancer vaccines, Checkpoint inhibitors

© 2016

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Clinical trials using various therapeutic vaccines.

Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer

Article Category: Research Article

Published Online: Sep 17, 2016

Page range: 4 - 16

Received: Feb 24, 2016

Accepted: Aug 04, 2016

DOI: https://doi.org/10.1515/fco-2016-0005

KeywordsCancer immunotherapy, Tumor infiltrating lymphocytes, Immunoscore, Cancer vaccines, Checkpoint inhibitors

© 2016

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Clinical trials using various therapeutic vaccines.

Keywords
Cancer immunotherapy, Tumor infiltrating lymphocytes, Immunoscore, Cancer vaccines, Checkpoint inhibitors